- Home
- PBYI vs MRCC Comparison
PBYI vs MRCC Comparison
Compare PBYI & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MRCC
- Stock Information
- Founded
- PBYI 2010
- MRCC 2011
- Country
- PBYI United States
- MRCC United States
- Employees
- PBYI N/A
- MRCC N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- PBYI Health Care
- MRCC Finance
- Exchange
- PBYI Nasdaq
- MRCC Nasdaq
- Market Cap
- PBYI 164.3M
- MRCC 176.4M
- IPO Year
- PBYI N/A
- MRCC 2012
- Fundamental
- Price
- PBYI $3.45
- MRCC $6.42
- Analyst Decision
- PBYI Strong Buy
- MRCC Hold
- Analyst Count
- PBYI 1
- MRCC 1
- Target Price
- PBYI $7.00
- MRCC $8.00
- AVG Volume (30 Days)
- PBYI 307.3K
- MRCC 84.7K
- Earning Date
- PBYI 07-31-2025
- MRCC 08-06-2025
- Dividend Yield
- PBYI N/A
- MRCC 15.67%
- EPS Growth
- PBYI 143.51
- MRCC 3301.50
- EPS
- PBYI 0.77
- MRCC 0.32
- Revenue
- PBYI $232,709,000.00
- MRCC $56,983,000.00
- Revenue This Year
- PBYI N/A
- MRCC N/A
- Revenue Next Year
- PBYI N/A
- MRCC N/A
- P/E Ratio
- PBYI $4.43
- MRCC $19.63
- Revenue Growth
- PBYI 2.68
- MRCC N/A
- 52 Week Low
- PBYI $2.23
- MRCC $6.11
- 52 Week High
- PBYI $4.13
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- PBYI 50.12
- MRCC 49.55
- Support Level
- PBYI $3.26
- MRCC $6.32
- Resistance Level
- PBYI $3.68
- MRCC $6.50
- Average True Range (ATR)
- PBYI 0.12
- MRCC 0.16
- MACD
- PBYI 0.00
- MRCC 0.02
- Stochastic Oscillator
- PBYI 52.90
- MRCC 52.08
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.